Literature DB >> 27809674

Structure-based QSAR, molecule design and bioassays of protease-activated receptor 1 inhibitors.

Weilong Zhong1, Pi Liu2, Qiang Zhang1, Dongmei Li1, Jianping Lin1,2,3.   

Abstract

Quantitative structure-activity relationship (QSAR) studies were performed on a series of protease-activated receptor 1 (PAR1) inhibitors to identify the key structural features responsible for their biological activity. Induced-fit docking (IFD) was used to explore the active mechanisms of all PAR1 inhibitors at the active pocket of PAR1, and the best plausible conformation was determined by IFD for further QSAR studies. Based on the best plausible conformation, structure-based descriptors and ligand descriptors incorporating the ligand-receptor interaction were calculated. The random forest method was used to select important descriptors and build the 2D-QSAR model. The results of the 2D-QSAR model gave a squared correlation coefficient (R2) of 0.937, a prediction squared correlation coefficient (R2pred) of 0.845 and a mean square error (MSE) of 0.056. Furthermore, a 3D-QSAR model was developed via topomer comparative molecular field analysis (Topomer CoMFA), resulting in an R2 of 0.938, a cross-validated Q2 of 0.503 and a R2pred of 0.758. Based on the developed QSAR model, Topomer search was used for virtual screening of the R2 fragment in lead-like inhibitors from the National Cancer Institute (NCI) database, which contains 260,000 molecules. Eighty-two compounds were designed with different R2 fragments, and four of these compounds were selected for further biological testing. All four compounds showed inhibitory potency against PAR1.

Entities:  

Keywords:  Topomer CoMFA; induced-fit docking; protease-activated receptor 1 inhibitors; quantitative structure–activity relationship; random forest

Mesh:

Substances:

Year:  2016        PMID: 27809674     DOI: 10.1080/07391102.2016.1234413

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  8 in total

1.  PredPromoter-MF(2L): A Novel Approach of Promoter Prediction Based on Multi-source Feature Fusion and Deep Forest.

Authors:  Miao Wang; Fuyi Li; Hao Wu; Quanzhong Liu; Shuqin Li
Journal:  Interdiscip Sci       Date:  2022-04-30       Impact factor: 3.492

2.  CircANXA2 Promotes Myocardial Apoptosis in Myocardial Ischemia-Reperfusion Injury via Inhibiting miRNA-133 Expression.

Authors:  Liang Zong; Weixin Wang
Journal:  Biomed Res Int       Date:  2020-06-24       Impact factor: 3.411

3.  MiR-145-5p Inhibits the Invasion of Prostate Cancer and Induces Apoptosis by Inhibiting WIP1.

Authors:  Jianming Sun; Linggang Deng; Ye Gong
Journal:  J Oncol       Date:  2021-12-02       Impact factor: 4.375

4.  Hypoxia Upregulates NOTCH3 Signaling Pathway to Promote Endothelial-Mesenchymal Transition in Pulmonary Artery Endothelial Cells.

Authors:  Li-Le Wang; Xiao-Li Zhu; Shu-Hua Han; Lu Xu
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-25       Impact factor: 2.629

5.  Drug screening and identification of key candidate genes and pathways of rheumatoid arthritis.

Authors:  Yu-Quan Shi; Wu-Fang Qi; Chun-Yu Kong
Journal:  Mol Med Rep       Date:  2020-05-21       Impact factor: 2.952

6.  Cartilage Oligomeric Matrix Protein promotes epithelial-mesenchymal transition by interacting with Transgelin in Colorectal Cancer.

Authors:  Weilong Zhong; Huiqin Hou; Tianyu Liu; Shuai Su; Xiaonan Xi; Yusheng Liao; Runxiang Xie; Ge Jin; Xiang Liu; Lanping Zhu; Hongxia Zhang; Xueli Song; Cheng Yang; Tao Sun; Hailong Cao; Bangmao Wang
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

7.  CircWEE1/miR-138 axis promotes the malignant progression of glioma by regulating SIRT1.

Authors:  Jinhui Guo; Lifang Yu
Journal:  Transl Cancer Res       Date:  2021-04       Impact factor: 1.241

8.  Circular RNA circCSPP1 promotes the occurrence and development of colon cancer by sponging miR-431 and regulating ROCK1 and ZEB1.

Authors:  Jin Wang; Lei Zhou; Bingxin Chen; Zhuwen Yu; Jianglei Zhang; Zhe Zhang; Chenrui Hu; Yanjin Bai; Xiaokang Ruan; Shengjia Wang; Jun Ouyang; Airong Wu; Xin Zhao
Journal:  J Transl Med       Date:  2022-01-31       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.